Related Experiment Videos
Low-level microsatellite instability in most colorectal carcinomas.
Päivi Laiho1, Virpi Launonen, Päivi Lahermo
1Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, FIN-00014 Helsinki, Finland.
Cancer Research
|February 28, 2002
Summary
Researchers investigated microsatellite instability (MSI) in colorectal cancer (CRC). Their findings suggest that microsatellite-stable (MSS) and low microsatellite instability (MSI-L) tumors share a common molecular origin, challenging distinct classifications.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colorectal cancers (CRCs) are classified as microsatellite stable (MSS) or high microsatellite instability (MSI-H), with a proposed MSI-low (MSI-L) group.
- The Bethesda panel is used to determine MSI status, but a clear definition for MSI-L remains elusive.
- Existing studies on MSI-L often use a limited number of markers, leading to ambiguity.
Purpose of the Study:
- To investigate the molecular and clinical features differentiating MSI-L from MSS colorectal cancers.
- To establish a reliable cutoff for MSI-L by analyzing a large number of markers and associated tumor characteristics.
- To determine if MSI-L represents a distinct biological entity or shares commonalities with MSS tumors.
Main Methods:
- Analysis of 90 BAT26 stable colorectal cancer samples using 377 microsatellite markers.
- Assessment of microsatellite instability (MSI) at 1-11 loci in the studied samples.
- Evaluation of K-RAS mutation, loss of heterozygosity, MLH1 and MGMT hypermethylation, and clinical features.
Main Results:
- Microsatellite instability was observed in 79% of cases (1-11 loci), indicating widespread low-level instability.
- No convincing molecular or clinical differences were found between putative MSI-L and MSS groups across various cutoff levels.
- The sensitivity of standard marker panels for detecting MSI-L was found to be very low.
Conclusions:
- The distinction between MSI-L and MSS colorectal cancers is not supported by distinct molecular or clinical features.
- MSS and MSI-L tumors likely share a common molecular background, suggesting a continuum rather than separate categories.
- Current marker panels may be insufficient for accurately classifying MSI-L tumors, necessitating a re-evaluation of MSI classification in colorectal cancer.